drugset / Trial / NCT01477749
Sipuleucel-T Manufacturing Demonstration Study
NaSingle-groupOpen-label
Summary
To demonstrate that sipuleucel-T can be successfully manufactured for subjects with metastatic castrate resistant prostate cancer (mCRPC) at a European manufacturing facility.
Timeline
- Start
- 2012-06
- Primary completion
- 2014-06
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sipuleucel-T | Cell therapy | 5e+07 cells | — |